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ABSTRACT
Purpose To investigateinsulinfibrillation under accelerated stress
conditions in the presence of a novel excipient, the molecular
chaperone α-crystallin, in comparison with common excipients.
Methods To induce fibrillation, recombinant human insulin
(0.58 mg ml
−1) formulations without excipient or with bovine
α-crystallin (0.01–0.2 mg ml
−1), human serum albumin (1–
5m gm l
−1), sucrose (10–100 mg ml
−1) or polysorbate 80
(0.075–0.3 mg ml
−1) were subjected to stirring stress in a
fluorescence well plate reader and formulation vials. Protein
fibrillation was monitored by thioflavin T. The formulations
were further characterized by size-exclusion chromatography,
light obscuration, UV/Vis and circular dichroism spectroscopy.
Results In both methods, insulin formed thioflavin T-binding
species, most likely fibrils. Addition of α-crystallin in the well
plate assay greatly improved insulin’s resistance to fibrillation,
measured as a 6-fold increase in fibrillation lag time for the
lowest and 26-fold for the highest concentration used, whereas
all other excipients showed only a marginal increase in lag time.
The stabilizing effect of α-crystallin was shown by all
characterization techniques used.
Conclusions The effect of α-crystallin on insulin’s physical
stability outperforms that of commonly used excipients. α-
Crystallin is proposed to bind specifically to pre-fibrillation
species, thereby inhibiting fibrillation. This makes α-crystallin an
interesting excipient for proteins with propensity to fibrillate.
KEY WORDS fibrillation.formulationdesign.insulin.
proteinexcipients.α-crystallin
ABBREVIATIONS
bis-ANS 4,4′-Bis(1-anilinonaphthalene 8-sulfonate)
FUV-CD Far ultraviolet circular dichroism
HP-SEC High performance size-exclusion chromatography
HSA Human serum albumin
NUV-CD Near ultraviolet circular dichroism
ThT Thioflavin T
INTRODUCTION
Protein pharmaceuticals are normally administrated by injec-
tions because of their poor absorption through oral, mucosal or
transdermal routes. Therapeutic proteins are formulated as a
liquid or lyophilized product comprising a suitable buffer and a
selection of excipients designed to maximize protein stability
(1,2). Furthermore, most formulations have to be kept in cold
storage, even when lyophilized, to prevent the degradation of
the therapeutic protein which can occur by chemical pathways
(deamidation, oxidation, etc.) or physical pathways (misfolding
or unfolding), which both can lead to the formation of
aggregates (reviewed in (1–4)). Aggregates compromise the
safety and efficacy of the therapeutic protein and may increase
its immunogenicity (5,6).
Due to the great diversity in protein sequence, structure
and, consequently, routes of degradation, no single formula-
tion strategy can be generally applied to all proteins. Instead, a
suitable tailor-made formulation will have to be developed for
each therapeutic protein. The search for novel excipients to
stabilize protein formulations is, therefore, an ongoing process.
An important problem related to therapeutic formula-
tions of primarily smaller proteins and peptides, such as
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is the formation of amyloid fibrils. Insulin is one of the best
described amyloid systems, and its fibrillation is considered
a nucleation-dependent process (8). The first step of the
fibrillation process is the reversible dissociation of
the insulin hexamer or tetramer to dimer or monomer.
The dimer or monomer unfolds to a partially folded
intermediate (9,10). The formation of this intermediate is
promoted by temperature, agitation and the presence of
air-water interface and surfaces (11,12). When a critical
concentration of partially folded intermediate is reached,
the formation of stable fibrillation nuclei, from which the
mature fibrils grow, are possible (9). This accumulation of
intermediates has very little apparent effect on the bulk
formulation. The events leading to formation of the nuclei
are generally referred to as the lag phase.
The formation of nuclei is followed by their extension
into fully grown fibrils (exponential growth phase). The
formation of the fibrillation nuclei is energetically unfavor-
able and suggested to be a stochastic event, where only a
single or very small number of nuclei are formed (13,14).
The dependency on a very limited number of events is
suggested to account for the high variance in lag time
generally observed in fibrillation studies (13,14). After the
formation of the first stable fibril, secondary nucleation,
where the formation of new nuclei is catalyzed by the
already formed fibrils, is proposed to explain the rapid
conversion of the bulk native protein to fibrils (13).
As prevention of protein fibrillation during production,
transport and storage remains a challenge to the pharma-
ceutical industry, we have evaluated α-crystallin, a member
of the small heat shock protein superfamily, as a novel anti-
fibrillation excipient in a formulation of recombinant
human insulin.
The novel excipient studied in this report, the
chaperone-like protein α-crystallin, is a polydisperse
oligomer native to the vertebrate eye lens. The oligomer
consists of 15–50 of the homologous αA and αB-crystallin
subunits in an estimated 3:1 ratio (15–17). As both subunits
have an approximate molecular mass of 20 kDa, the
polydisperse oligomer has a size range between 300 and
1,000 kDa (15). The physiological function of α-crystallin is
to prevent protein aggregates (also called cataracts) from
forming in the eye lens (18). This chaperone-like effect of α-
crystallin has also been shown in a range of protein systems
in vitro ((18,19) and reviewed in (20,21)). The proposed
mechanism of the protective effect of α-crystallin is an
interaction with the exposed hydrophobic surfaces of
partially denatured or misfolded proteins (22,23), thereby
preventing their self-association and irreversible aggrega-
tion. The chaperone-like function of α-crystallin is inde-
pendent of chemical energy input and highly selective for
destabilized proteins (24). α-crystallin activity is further
enhanced above physiological temperature, which increases
the capacity and affinity for binding its substrates (19,25).
Several members of the small heat shock protein super-
family, including α-crystallin, are reported to be effective
inhibitors of amyloid fibrillation (26,27).
The aim of this study was to test α-crystallin as a
stabilizing excipient for recombinant human insulin, a
therapeutic protein with a propensity to fibrillate. The
stabilizing effect of α-crystallin was compared to that of
human serum albumin (HSA), a protein excipient used
commonly in several therapeutic protein formulations
(28,29). HSA has been claimed to have some chaperone-
like function (30). Furthermore, we also compared α-
crystallin activity against the widely used excipients
polysorbate 80 (commercially known as Tween® 80) and
sucrose (28). The stabilizing effect of the excipients was
tested in two insulin fibrillation assays, both applying
stirring to stress the formulations, one in a fluorescence
well plate and one in a formulation vial.
MATERIALS AND METHODS
Materials
Recombinant human insulin was kindly donated by
Schering-Plough (Oss, the Netherlands). HSA and bovine
α-crystallin were procured from Sigma-Aldrich (St. Louis,
US) and used without further purification. Polysorbate 80
was purchased from Merck-Schuchardt (Hohenbrunn,
Germany). All other chemicals were of analytical grade.
Insulin was dissolved in a minimal amount of 0.05 M
hydrochloric acid, then diluted in a large excess of
phosphate buffer (50 mM phosphate with 100 mM NaCl
and adjusted to pH 7.4 with sodium hydroxide). HSA and
α-crystallin were dissolved directly in the phosphate buffer.
The concentrations were determined by UV absorption,
using a molecular weight of 5,808 g·mol
−1 and ε276 nm of
6,200 M
−1 cm
−1 for insulin (31) and a molecular weight of
66,500 g·mol
−1 and ε279 nm of 35,300 M
−1 cm
−1 for HSA
(32). For α-crystallin, a molecular weight of 19,852 g mol
−1
and an ε280 nm of 13,300 M
−1 cm
−1 for an average
monomer was used, based on a 3:1 αAt oαB-crystallin ratio
as described in (33).
Insulin Formulations
The formulations were prepared as 0.58 mg ml
−1 insulin
(0.1 mM) in phosphate buffer. The zinc content of the
insulin formulation was approximately three zinc ions per
hexamer. Three formulations were used in the vial assay
(see below): an insulin formulation with no addition of
excipient, a formulation containing 0.2 mg ml
−1 α-crystallin
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−1 HSA. The insulin
formulation used in the well plate assay (see below) either
contained no excipients or was co-formulated with α-
crystallin (0.01–0.2 mg ml
−1), HSA (1–5m gm l
−1), sucrose
(10–100 mg ml
−1) or polysorbate 80 (0.075–0.3 mg ml
−1).
Vial Assay
The insulin formulations (4 ml) were transferred into 6 ml
Ø 20 mm glass type 1 vials with a Teflon-coated rubber
stopper. The samples were stirred in upright position using
a 12 mm Ø 4 mm Teflon-coated stirring bar on a
multipoint magnet stirrer set at 750 rpm. The experiments
were carried out at 5°C, 25°C and 45°C (±1°C). The
stirring was ensured to be symmetrical so the formulation
had no contact with the vial neck or stopper. Samples were
taken out and analyzed using high performance size-
exclusion chromatography (HP-SEC), fluorescence and
UV spectroscopy, circular dichroism, and light obscuration.
Well Plate Assay
An accelerated stress study was set up in a FLUOstar
OPTIMA (BMG, Offenburg, Germany) fluorescence plate
reader. Two-hundred μLo ft h ef o r m u l a t i o nw i t h2 0μM
thioflavin T (ThT) present was transferred into the wells of
a polystyrene 96-well plate (Nunc, Rochester, US). A
3 mm glass bead (Whitehouse Scientific, Waverton, UK)
was put in each well to ensure reproducible stirring, and
the plate was covered using polyolefin sealing tape (Nunc,
Rochester, US) to prevent evaporation. The plate was
shaken using 600 rpm double orbital shaking mode at
45°C. ThT fluorescence was measured with 400 s interval
with an excitation filter at 450 nm and an emission filter at
480 nm.
The ThT signal from the experiments was evaluated
with respect to lag time and exponential phase rate
constant. The lag time was defined as the time point where
10% of the maximum fluorescence is reached. The rate
constant of the exponential phase was calculated using a
fitting of the sigmoidal fibrillation curve in GraphPad Prism
4.0 based on the Finke-Watzky equation (34) and assuming
that all insulin was converted to fibrils in the reaction.
Stability of the Excipient
The loss of soluble α-crystallin and HSA was followed
during the fibrillation of insulin using the settings from the
well plate assay. To quantify the excipient during insulin
fibrillation, the fluorescence signal of three wells was
recorded, and the samples from these wells were taken
out and analysed using HP-SEC as described below. This
procedure was repeated at each time point.
High Performance Size-Exclusion Chromatography
The quantification of native protein fraction was performed
on two different HP-SEC systems. The first one consisted of
a 515 pump, a 717 autosampler (Waters, Milfort, US) and
a SPD UV/Vis detector (Shimadzu, Kyoto, Japan), using a
TSK 3,000 SWXL column (Tosoh, Tokyo, Japan). The
mobile phase used was 100 mM ammonium acetate, pH
6.8, with 0.3 M sodium chloride. The second system used
consisted of an L7100 pump, an L7200 autosampler and
an L7400 UV/Vis-detector (Merck-Hitachi, Darmstadt,
Germany). The column used was a TSK 4,000 SWXL
column (Tosoh, Tokyo, Japan) and the mobile phase a
50 mM phosphate buffer, pH 7.4, with 100 mM NaCl. No
apparent difference in the protein quantification was
observed with the two systems. For both systems 50–
150 μl samples were injected, and separation was performed
at a flow rate of 0.5 ml/min. The absorbance at 276 nm
was recorded, and the areas of the peaks were determined.
Fluorescence Spectroscopy
Steady state fluorescence emission scans were collected on
a FLS 920 spectrometer (Edinburgh Instruments Ltd.,
Livingston, UK) fitted with a plate reader. The samples
from the formulations were diluted 5-fold. ThT was used
in an end concentration of 5 μMa n d4 , 4 ′-Bis(1-anilino-
naphthalene 8-sulfonate) (bis-ANS) in an end concentra-
tion of 1 μM. ThT-containing samples were excited at
442 nm, and emission at 482 nm was recorded; bis-ANS
excitation was at 385 nm, and the emission value at
488 nm was recorded. The values were accumulations of 3
measurements with a dwell time of 0.5 s and slit widths of
6 nm. The fluorescence signal was normalized to the value
of an unstressed formulation containing bis-ANS.
Circular Dichroism
The experiments were performed on a JASCO J-815
circular dichroism spectrometer (Jasco, Tokyo, Japan).
The insulin samples were scanned in a 1-cm quartz sample
cell from 300 to 250 nm and in a 1-mm quartz sample cell
between 240 and 195 nm, using a bandwidth of 2 nm, a
response time of 2 s and a scan rate of 100 nm·min
−1. Each
spectrum was an average of three scans, and a reference
scan of the relevant buffer was subtracted.
UV Spectroscopy
UV spectroscopy was performed on an 8,453 UV/VIS
spectrometer (Agilent, Santa Clara, US). The spectra were
obtained between 190 and 400 nm in a 10-mm quartz cell
and corrected for the respective buffer signal.
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The number and size of subvisible particles was measured
using light obscuration, a method described in the
European pharmacopeia (35). Light obscuration is based
on the amount of light blocked as suspended particles pass a
light beam. The measurements were performed on a
SVSS-C system (PAMAS GmbH, Rutesheim, Germany)
set with a pre-run volume of 300 μl and three measure-
ments of 200 μl. The number of particles ranging in size
from 1–50 μm was collected.
RESULTS
The insulin formulations were tested in two different
fibrillation assays, both applying stirring to stress the
formulations. One was performed in fluorescence well
plates placed in a fluorescence plate reader for online
measurement of fibrillation kinetics. The other one was
p e r f o r m e di nf o r m u l a t i o nv i a l sa n du s e df o rf u r t h e r
characterization of the formulations with a range of
analytical methods. In both assays, insulin is in contact
with the liquid-air interface and glass and plastic surfaces,
conditions, which are known to induce fibrillation (11,36).
Vial Assay
The vial assay was carried out in formulation vials with
magnet stirring at three different temperatures (45°C, 25°C
and 5°C), as described in experimental procedures. The
three formulations were each incubated in triplicate, and
samples taken at regular intervals were analyzed for ThT
(added prior to analysis) fluorescence and for native insulin
recovery using HP-SEC. The HP-SEC method showed
baseline-separated peaks of the three proteins in the
formulations (Fig. 1) and can thus be used for quantification
of non-fibrillated insulin and excipient.
Characterization at 45°C
Over the 8-hour time course of the stirring experiment at
45°C and in the absence of excipients, soluble insulin
completely disappeared from the solution, as observed by
HP-SEC. A corresponding rise in ThT signal suggests that
the primary degradation product is fibrils (Fig. 2A). The
presence of α-crystallin (0.2 mg ml
−1) completely prevented
the formation of ThT-binding species. A small decrease
(<10%) in the native insulin fraction was observed for all
three vials, possibly due to formation of non-ThT-binding
aggregates. Also, the use of HSA significantly limited the
formation of ThT-binding species compared to the plain
insulin formulation (Fig. 2A). However, the loss of native
fraction was in the range of 10–30% over the 8-hour course
of the experiment. ThT is generally considered selective for
amyloid structure, but random aggregates with little or no
ThT-binding capability can also be formed in the assay.
Most aggregates, including fibrils, show affinity for bis-
ANS, a commonly used probe for hydrophobicity (37). The
bis-ANS fluorescence results (Fig. 3) showed that the insulin
formulation contained physical degradation products inter-
acting with bis-ANS. In contrast, the α-crystallin-containing
insulin sample did not show bis-ANS-binding physical
degradation products. This suggests that α-crystallin pre-
vented the formation of random aggregates of insulin.
Native HSA binds bis-ANS due to its hydrophobicity and
gave a large background signal in our experiments. Thus,
no measurements were carried out on the HSA-containing
formulation.
Optical density of the formulations was measured at
350 nm (Fig. 4A), and subvisible particles were quantified
using light obscuration (Fig. 4B). The unstressed formula-
tions generally had an optical density of less than 0.04, and
subvisible particle (<50 μm) counts were in the range 4–
8∙10
3 particles∙ml
−1.
The stressed excipient-free insulin formulations showed
an optical density of 2.2 as well as an increase in particle
count to 2.5∙10
5 particles∙ml
−1. The formulations containing
α-crystallin showed no significant increase in optical density,
but an increase in particle count to 2.7∙10
4 particles∙ml
−1.
The formulation containing HSA showed a substantial
increase in both optical density (1.2) and particle count
(2.2∙10
5 particles∙ml
−1).
In order to study whether the protein excipients
themselves aggregate in the assay, two samples containing
only α-crystallin or HSA were tested; both showed an
increase in subvisible particle count (2.0∙10
4 and 1.4∙10
5
particles∙ml
−1, respectively). In addition, the HSA sample
showed a moderate increase in optical density to 0.37.
Fig. 1 Chromatograms of unstressed insulin (0.58 mg ml
−1) containing
2.5 mg ml
−1 HSA (A), 0.2 mg ml
−1 α-crystallin (B) and no excipient (C).
Peak 1 is α-crystallin, the two peaks 2 are HSA monomer and dimer, and
peak 3 is insulin. The void and total column volumes are 5 and 15 ml,
respectively.
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−1), in the absence of stabilizer or in the presence of α-crystallin (0.2 mg ml
−1) or HSA 2.5 mg ml
−1 in
the vial assay as measured in triplicate (each line and symbol representing a replicate) by ThT fluorescence (upper panels) and HP-SEC (lower panels). The
experiment was done at three temperatures: 45°C (A), 25°C (B) and 5°C (C). The observed standard deviations on three measurements of the same
sample via both methods were less than 5%. The time scale is different between the panels.
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assay, with α-crystallin showing less particle formation than
HSA.
Circular dichroism, in both the near-UV (NUV-CD)
and the far-UV range (FUV-CD), was performed in order
to determine the tertiary and secondary structure, respec-
tively, of insulin and α-crystallin. The FUV-CD spectrum of
the unstressed insulin formulation, with minima at 222 and
208 nm (Fig. 5A), is typical for α-helical structure. The
NUV-CD spectrum shows a minimum at 276 nm (Fig. 5B).
The intensity and shape of the latter signal is related to
dimer and hexamer formation of insulin (38). The signal of
α-crystallin was so small in both FUV-CD (Fig. 5C) and
NUV-CD (Fig. 5D) that it could be subtracted from the
signal of the whole formulation, yielding the signal of
insulin alone. In contrast, the large CD signal of HSA could
not be properly subtracted, due to its large excess
concentration (w/w) compared to insulin. Thus, the insulin
structure could not be determined by CD in the presence of
HSA.
Thestressedinsulinformulations showedasubstantialloss
of α-helical structure, as indicated by the lack of the minima
in the FUV-CD spectrum. The NUV-CD spectrum of the
stressed formulation has no distinct features, and is typical of
light scattering effects. In the presence of α-crystallin, no
changes in the spectra were observed by FUV-CD (Fig. 5A),
while the NUV-CD (Fig. 5B) showed a slight decrease in
the (negative) signal. This suggests a slight loosening of the
tertiary structure or dissociation of insulin, an effect which
could be caused by α-crystallin, as we reported earlier (33).
To further examine the stability of α-crystallin, spectra were
taken of unstressed and stressed α-crystallin with no insulin
present. Both in FUV-CD (Fig. 5C) and NUV-CD
(Fig. 5D), only small changes in the spectra were observed,
suggesting only minor perturbation of the α-crystallin
structure.
Stability Study at 25 and 5°C
At 25°C, the experiment was performed for 32 h to obtain
a reasonable amount of physical degradation. In the course
of the experiment, the excipient-free insulin formulation
lost 10–50% of the native fraction, with a corresponding
increase in ThT fluorescence (Fig. 2B). The use of α-
crystallin limited the loss of native insulin to between 0 and
10%, while HSA limited the loss to 5–20%, with
corresponding increases in ThT signal observed for both
formulations.
At 5°C, the experiment was carried out for 20 days
(Fig. 2C). The loss of native fraction in the excipient-free
insulin formulation was 35–50% with a corresponding rise
in ThT fluorescence. No significant loss of soluble insulin in
the formulation containing α-crystallin and no increase in
ThT signal was observed. For the HSA-containing formu-
lation, a loss of 15–50% of the native insulin fraction was
observed, with corresponding increase in ThT signals.
These results show that α-crystallin also has a protective
effect at lower temperatures, limiting the aggregation
Fig. 3 Physical degradation of
insulin (0.58 mg ml
−1)( A)a n d
insulin formulated with
0.2 mg ml
−1 α-crystallin (B)i nt h e
vial assay as measured in triplicate
(each line and symbol representing
a replicate) at 45°C as measured
by bis-ANS fluorescence. For the
HSA-containing formulation, the
high background signal originating
from interaction of bis-ANS with
HSA interfered with the analysis.
Fig. 4 Representative examples
of data collected in the vial assay
at 45°C after 8 h. (A) optical
density at 350 nm; (B) number
of subvisible particles by light
obscuration. For both methods,
only minor variance between
measurements of the same
sample was observed.
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than HSA.
Well Plate Assay
The insulin formulations with addition of varying concen-
trations of α-crystallin (0.02–0.2 mg ml
−1), HSA (1–
5m gm l
−1), sucrose (1–10% w/v) and polysorbate 80
(0.0075–0.03% w/v) were stressed by shaking at 45°C in a
fluorescence well plate reader, and the formation of ThT-
binding species was continuously monitored.
For all insulin formulations, the stress resulted in the
appearance of ThT-binding species starting with a lag
phase (constant low signal), followed by an exponential
phase (signal increases exponentially), and ending in an
equilibrium phase (constant high signal). Examples are
shown for insulin with increasing amounts of α-crystallin
and HSA in Fig. 6A & B, respectively. The binding of ThT,
a probe selective for amyloid structures, and the character-
istic sigmoidal shape of the fluorescence-time curve indicate
that fibrils were formed (39). Moreover, insulin is known to
fibrillate under comparable shaking stress conditions (10).
Fig. 5 The top row shows the
circular dichroism spectra of the
insulin formulations (0.58 mg ml
−1)
in the far-UV (A) and near-UV (B)
regions. The spectra of the insulin
formulation without excipient are
shown as a solid line (unstressed)
and dotted line (stressed). The
spectra of the α-crystallin-
containing insulin formulation
are shown as a dashed line
(unstressed) and a dash-dotted line
(stressed). Spectra A and B are
normalized to insulin concentra-
tion. In the bottom row, spectra of
α-crystallin in the absence of insulin
are shown in the far-UV (C)a n d
near-UV (D) region. Unstressed
(solid) and stressed (dotted line) α-
crystallin (0.2 mg ml
−1)s a m p l e s
are shown. Spectra C and D
are normalized to α-crystallin
concentration.
Fig. 6 Fibrillation of insulin in the
presence of either no excipient,
HSA or α-crystallin as observed by
ThT fluorescence. (A) Examples
of fibrillation curves of insulin with
the addition of 0 (1), 0.02 (2),
0.04 (3), 0.08 (4), 0.2 mg ml
−1
(5) α-crystallin. (B) Examples of
fibrillation curves of insulin con-
taining either 0 (1), 1 (2), 2.5 (3),
or 5 mg ml
−1 (4) HSA. Control
samples containing only α-
crystallin or HSA showed only
minor ThT-fluorescence intensity,
which did not change during the
course of the experiment. The
lines are for guidance purposes
only. (C) Fibrillation lag time as a
function of α-crystallin concentra-
tion. (D) Lag time as a function of
HSA concentration. The plotted
point is an average of 7 repeats
and the error bars represent the
standard deviation.
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showed only a marginal ThT fluorescence signal and no
increase during the course of the experiment (data not
shown). Thus, no fibril formation was observed for the
protein excipients.
The physical stability of the formulations was ranked
using the parameter’s lag time and reaction rate in the
exponential phase as described in experimental procedures.
The lag time measured in the insulin formulation was 2.3±
0.3 h, while the apparent reaction rate was 2.2±0.3 h
−1
(Fig. 6 & Table I). Increasing α-crystallin concentrations
progressively prolonged the lag time to 60±16 h at
0.2 mg ml
−1 and also lowered the reaction rate to 0.4±
0.1 h
−1 (Fig. 6A,C & Table I). Higher concentrations of α-
crystallin were tested, but no further increase in the lag time
was observed (data not shown). For HSA, a low but
statistically significant protective effect was obtained at
concentrations of 2.5 mg ml
−1 (lag time of 3.5±0.8 h) and
higher (Fig. 6B,D & Table I). The reaction rate decreased
significantly at all concentrations, with the lowest (0.5±
0.1 h
−1) at 5 mg ml
−1 (Table I). The use of 10% sucrose
also yielded a small but significant increase in the lag time
Fig. 7 The upper (A and B)
show insulin (0.58 mg ml
−1)
fibrillation as observed by fraction
of soluble insulin by HP-SEC
(●, solid line) and fraction of the
maximum ThTsignal (▼, dash
dotted line). The fibrillation was
performed in the presence of
0.01 mg ml
−1 α-crystallin (A) and
2.5 mg ml
−1 HSA (B). The
soluble fraction of the excipients in
the same experiment is shown
in (C) and (D) for α-crystallin and
HSA, respectively. The panels
show the remaining excipient
fractions in the presence of insulin
(■, dotted line) and a control stress
experiment where no insulin
was present (▲, dashed line), as
determined by HP-SEC. The
error bars show the standard
deviation of three separate
samples. The lines are for
guidance purposes only.
Excipient Concentration
(mg·ml
−1)
Approximate molar ratio
(insulin: excipient)
a
Lag time (hours) Exponential phase
reaction rate (hours
−1)
None −− 2.3±0.3 2.2±0.3
α-crystallin 0.02 100 : 1 13±7.5* 0.8±0.3*
0.04 50 : 1 28±16* 0.8±0.3*
0.08 25 : 1 51±16* 0.5±0.2*
0.2 10 : 1 60±16* 0.4±0.1*
HSA 1.0 7 : 1 2.7±0.2 1.1±0.2*
2.5 3 : 1 3.5±0.8* 0.6±0.1*
5.0 1 : 1 3.4±0.3* 0.5±0.1*
Sucrose 10 1 : 300 2.4±0.2 1.9±0.6
50 1 : 1,500 2.5±0.1 2.1±0.3
100 1 : 3,000 2.7±0.2* 1.9±0.1
Polysorbate 0.075 2 : 1 2.5±0.2 4.3±0.5*
0.15 1 : 1 3.0±0.4* 3.2±0.5*
0.30 1 : 2 3.4±0.3* 2.5±0.3*
Table 1 Effect of the excipients
on insulin fibrillation lag time and
growth rate in the well plate assay
aThe molar ratio is calculated based
on monomeric form of the
proteins.
*Statistically different from that of
the insulin formulation without
excipient with a
95% confidence limit using
a student t-test.
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significant increase in lag time both at 0.015% and 0.03%,
with the longest lag time (3.4±0.3 h) at 0.03% (Table I).
Neither polysorbate 80 nor sucrose significantly decreased
the reaction rate, and polysorbate 80 surprisingly increased
it, especially at the lowest concentration tested (Table I).
Stability of the Excipient
The concentration of the soluble fraction of protein
excipients during insulin fibrillation was followed by HP-
SEC during the course of a well plate experiment. The
excipient concentrations were 0.01 and 2.5 mg ml
−1 for α-
crystallin and HSA, respectively. Insulin fibrillation in both
experiments was observed after 3–5 h (Fig. 7A & B). The
soluble fraction of α-crystallin declined more rapidly in the
presence of stressed insulin than in a control sample with no
insulin present (Fig. 7C). As the α-crystallin peak declined,
new peaks were observed at smaller elution volumes,
suggesting that initially soluble aggregates were formed
(Fig. 8). The rapid decline in soluble insulin concentration
as well as the rise in ThT signal only occurred when soluble
α-crystallin (or soluble aggregates) was no longer detected
in the HP-SEC chromatograms (compare Fig. 7A & C). For
HSA, a steady decline in peak area was observed with no
apparent effect on the presence of stressed insulin (compare
Fig. 7B & D). This suggests that α-crystallin binds to and
co-aggregates with a fibrillation-prone intermediate of
insulin, whereas HSA probably does not (or only to a very
limited degree). Furthermore, the presence of soluble α-
crystallin prevents the formation of ThT-binding species,
whereas HSA does not (Fig. 7).
DISCUSSION
We have investigated the effect of the molecular chaperone
α-crystallin as an anti-fibrillation excipient, compared to
HSA, polysorbate 80 and sucrose.
The use of α- c r y s t a l l i ni nt h ei n s u l i nf o r m u l a t i o n
increased the lag time of insulin fibrillation up to 26-fold
for the highest concentration used (0.2 mg ml
−1). In
contrast, polysorbate 80, sucrose and HSA, even at higher
concentrations, only increased the lag time by a factor of
1.5, 1.2 and 1.5, respectively (Table I). Even the lowest
concentration of α-crystallin used (0.02 mg ml
−1) provided
a 6-fold prolongation of the lag time. The stirring stress
method in vials at 45°C showed some formation of particles
in the α-crystallin-containing formulation in the subvisible
range, but no increase in optical density (Fig. 4). Our
structural data (Fig. 5) on the stressed vial formulations
show little or no perturbation of the insulin structure when
α-crystallin was present. In contrast, significant loss of
structure of insulin was observed in the excipient-free
formulation. Also, control samples containing only α-
crystallin showed little loss of structure after 8 h incubation.
HSA showed a clearly lower protective effect (Fig. 2) and
a high increase in particle count and optical density (Fig. 4).
The latter suggest that HSA itself aggregated in the assay.
The results from our vial assay at 5 and 25°C also showed
that the stabilizing effect of α-crystallin is not limited to high
temperatures, even though its chaperone-like capabilities
have been reported to increase above physiological tem-
perature (19,24,25). At all temperatures, the α-crystallin-
containing formulation outranked the other formulations,
both in terms of fibrils formed and remaining native
fraction at the end of the experiment (Fig. 2). In conclusion,
the effect of α-crystallin in both assays was far superior to
that of all other excipients used.
The common excipients used in the assays stabilize
insulin through various mechanisms. The non-ionic surfac-
tant polysorbate 80 and HSA probably prevent insulin
adsorption to container surfaces and the air–water interface
through preferential adsorption (1,29). Protein adsorption
to interfaces is known to promote formation of partially
folded protein intermediates. Thus, a reduced adsorption of
insulin lowers the formation rate of fibrillation-prone
species. The excipient sucrose is preferentially excluded
from the protein surface domain and thereby reduces the
population of partly denatured and misfolded species (40).
In addition, the preferential exclusion effect will stabilize
higher association states of insulin, i.e., the hexamer and
dimer, but also fibrils. The common excipients are thus
all expected to reduce the accumulation of partially
folded intermediates and nuclei, albeit through different
mechanisms. Nonetheless, only a very marginal protective
effect of the excipients, compared to α-crystallin, was
Fig. 8 Chromatograms of insulin (0.58 mg ml
−1) formulations containing
0.1 mg ml
−1 α-crystallin stressed for 0 to 8 h as denoted on the graph.
Peak A is soluble aggregates, peak B is α-crystallin and peak C is insulin.
The insulin signal is truncated to focus on the α-crystallin and aggregate
peaks. The void and total column volume are 5 and 15 ml, respectively.
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protein formulations.
The exponential phase rate constants in formulations
containing α-crystallin or HSA decreased about 4-fold
(Table I). Thus, both excipients have a moderate effect on
the elongation of fibrils. As both proteins are reported to
interact directly with proteins (23,29), this effect could be
due to association with intermediate species, thus delaying
their addition to fibrillar species. However, a direct
interaction with the growth site of the fibrils cannot be
excluded based on our data.
Soluble α-crystallin, but not HSA, disappears from the
solution prior to the fibrillation of insulin (Figs. 7 & 8). This
indicates the formation of eventually insoluble co-
aggregates with pre-fibrillar insulin species. This is in
agreement with recent studies on the mechanism of sup-
pression of amyloid fibrillation by small heat shock proteins
(26,27,41). Dual polarization interferometry studies have
shown that inhibition of α-synuclein fibrillation by α-
crystallin occurs prior to formation of ThT-binding species
(26). A mechanism of amyloid fibrillation inhibition has
recently been suggested in a review by Ecroyd & Carver
(42), based on the nucleation-dependent polymerization
model of fibrillation (43). It describes the binding by small
heat shock proteins to occur to all non-native fibrillation-
prone species, including mono/dimeric intermediates and
fibrillation nuclei. This isplausible, as α-crystallin is suggested
to be specific to partially denatured or misfolded proteins (24),
descriptions that fit well with the proposed structure of the
intermediate species in the insulin fibrillation pathway
(10,12). Fibrillation nucleation is described as a stochastic
event, where one or only a few nuclei are formed (13).
Subsequently, autocatalysis (secondary nucleation) through
the first formed fibrils (13) results in the conversion of bulk
native insulin to insoluble fibrils. Inhibition at this critical step
in fibrillation could account for the increase in insulin stability
observed in our assays. In conclusion, the direct interaction
with intermediates leading to the formation of the critical
fibrillation nucleus is most likely responsible for the superior
effect of α-crystallin compared to all other excipients.
We have demonstrated that α-crystallin is an effective
inhibitor of fibrillation in a formulation of the therapeutic
protein insulin. Expression and purification of recombinant
human α-crystallin for excipient use is feasible and can be
expectedtohavesimilaractivity tothebovine α-crystallin tested
in this work (44,45). There are, however, several unknown
factors that may oppose the commercial use of α-crystallin as
an excipient. First, several members of the small heat shock
family have been implicated in immuno-activating effects
(46–48), thus potentially stimulating unwanted immunologi-
cal reactions towards the therapeutic protein. Second, its
long-term stability is as yet unknown. However, since it is
effective in very low concentrations the presence of α-
crystallin degradation products may not be a significant
problem, as long as functionality is retained. Third, the
interaction with other potential excipients, e.g., phenolic
preservatives, is unknown. Binding of these compounds to α-
crystallin, and subsequent loss of activity of either, will need
to be determined. Finally, α-crystallin may be problematic in
some analytical assays, due to interference. However,
(recombinant) HSA is currently in use as a stabilizing additive
in some protein formulations at much higher concentrations
than those that would be required for α-crystallin.
CONCLUSIONS
The molecular chaperone α-crystallin shows a superior
stabilizing effect on insulin compared to the other tested
excipients, HSA, polysorbate 80 and sucrose. The favorable
stabilizing action of α-crystallin is proposed to be due to
specific interaction between α-crystallin and all non-native
insulin species involved in the fibrillation process. This
interaction delays formation of the fibrillation nucleus and
thus the physical degradation of the bulk protein. This
makes small heat shock proteins interesting candidates as
excipients in formulations of insulin and other therapeutic
peptides and proteins with propensity to fibrillate.
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